Clinical Trials Logo

Recurrent Ovarian Cancer clinical trials

View clinical trials related to Recurrent Ovarian Cancer.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT03025867 Approved for marketing - Clinical trials for Recurrent Ovarian Cancer

Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer

Start date: n/a
Phase: N/A
Study type: Expanded Access

This is an expanded access program (EAP) for eligible patients with Recurrent Ovarian Cancer. This program is designed to provide access to niraparib prior to approval by the US Food and Drug Administration (FDA). To be eligible, patients with Recurrent Ovarian Cancer following a partial (PR) or complete response (CR) to their most recent platinum-based chemotherapy and must have experienced a PR or CR after the penultimate (next to last) platinum-based chemotherapy for at least 6 months without disease progression after this chemotherapy.